Research programme: cyclin-dependent kinase inhibitors - Cyclacel

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Cyclacel

Alternative Names: 2-Anilino-4-(thiazol-5-yl)-pyrimidine - Cyclacel; CCT-68127; CYC 11056; CYC400 series - Cyclacel; Second-generation CDK inhibitors - Cyclacel; Tri-substituted purines - Cyclacel

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Purines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Cancer; Glomerulonephritis; Neuroblastoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom (PO)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 23 Nov 2015 Preclinical trials in Neuroblastoma in United Kingdom (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top